News Summary
NegativeCME Group beat Q2 2026 earnings expectations with record market data revenue, but faces a significant regulatory headwind: a high-profile lawsuit against the CFTC over perpetual futures approvals, with CEO Terry Duffy publicly opposing the products. Analyst price targets have been trimmed by ~$2–$7 amid concerns about softer revenue growth and competitive pressures, creating mixed forward momentum despite near-term operational strength.
Red flags
- •Litigation against primary regulator (CFTC) over perpetual futures approvals—highly unusual and creates regulatory uncertainty
- •CEO publicly opposing regulator-approved product category, signaling strained regulator relationship
- •CFTC blocked CME's 24/7 crude oil trading launch—regulatory constraint on growth initiatives
- •Analyst price targets trimmed; consensus concerns about slowing revenue growth and new competition
- •Potential strain in FanDuel partnership over perpetual futures dispute
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Point72 | Steve Cohen | 744K | +654K | $164M | 0.3% | +726% | Existing |
| Baupost Group | Seth Klarman | 619K | +619K | $137M | 2.5% | — | NEW |
| Viking Global | Andreas Halvorsen | 153K | +153K | $34M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where CME ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #14 of this fund's book
- 11TELEFLEX INCORPORATED$179M
- 12NORWEGIAN CRUISE LINE HLDGS$163M
- 13MOLINA HEALTHCARE INC$145M
- 14CME GROUP INC$137M
- 15HERBALIFE LTD$122M
- 16EAGLE MATLS INC$119M
- 17GDS HLDGS LTD$113M
Values are quarter-end position sizes. Shown only for funds where CME ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Vanguard Capital Management | SC 13G | 27.0M | 7.5% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.